Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2019 Jan 13

PMID 30635448

Citations 17

Authors

Michael J Birrer

Ilaria Betella

Lainie P Martin

Kathleen N Moore

Affiliations

Soon will be listed here.

Abstract

Prognosis for women with epithelial ovarian cancer remains poor. One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα). This commentary discusses the characteristics that contribute to its attractiveness as a candidate for therapeutic intervention.

Citing Articles

Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?.

Bukowski K, Rogalska A, Marczak A Int J Mol Sci. 2024; 25(22).

PMID: 39595996 PMC: 11593442. DOI: 10.3390/ijms252211927.

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.

OMalley D, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D Future Oncol. 2024; 20(32):2423-2436.

PMID: 39082675 PMC: 11520569. DOI: 10.1080/14796694.2024.2372241.

Effects of solid lipid nanocarrier containing methyl urolithin A by coating folate-bound chitosan and evaluation of its anti-cancer activity.

Al-Fatlawi I, Pouresmaeil V, Davoodi-Dehaghani F, Pouresmaeil A, Akhtari A, Homayouni Tabrizi M BMC Biotechnol. 2024; 24(1):18.

PMID: 38600497 PMC: 11005287. DOI: 10.1186/s12896-024-00845-6.

Recent advances of novel targeted drug delivery systems based on natural medicine monomers against hepatocellular carcinoma.

Ji G, Li Y, Zhang Z, Li H, Sun P Heliyon. 2024; 10(2):e24667.

PMID: 38312669 PMC: 10834828. DOI: 10.1016/j.heliyon.2024.e24667.

The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer.

McFadden M, Singh S, Kinnel B, Varambally S, Singh R J Ovarian Res. 2023; 16(1):220.

PMID: 37990267 PMC: 10662420. DOI: 10.1186/s13048-023-01308-w.

References

Kovtun Y, Audette C, Ye Y, Xie H, Ruberti M, Phinney S . Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006; 66(6):3214-21. DOI: 10.1158/0008-5472.CAN-05-3973. View

Maurer A, Elsinga P, Fanti S, Nguyen B, Oyen W, Weber W . Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J Nucl Med. 2014; 55(5):701-4. DOI: 10.2967/jnumed.113.133074. View

Moore K, Martin L, OMalley D, Matulonis U, Konner J, Perez R . Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2016; 35(10):1112-1118. PMC: 5559878. DOI: 10.1200/JCO.2016.69.9538. View

Naumann R, Coleman R, Burger R, Sausville E, Kutarska E, Ghamande S . PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013; 31(35):4400-6. DOI: 10.1200/JCO.2013.49.7685. View

Fisher R, Siegel B, Edell S, Oyesiku N, Morgenstern D, Messmann R . Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008; 49(6):899-906. DOI: 10.2967/jnumed.107.049478. View

OShannessy D, Somers E, Maltzman J, Smale R, Fu Y . Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus. 2013; 1:22. PMC: 3725886. DOI: 10.1186/2193-1801-1-22. View

Moore K, Martin L, OMalley D, Matulonis U, Konner J, Vergote I . A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2017; 14(2):123-136. DOI: 10.2217/fon-2017-0379. View

Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C . A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. J Clin Oncol. 2016; 34(19):2271-8. DOI: 10.1200/JCO.2015.63.2596. View

Zhao X, Li H, Lee R . Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008; 5(3):309-19. DOI: 10.1517/17425247.5.3.309. View

10.

Ab O, Whiteman K, Bartle L, Sun X, Singh R, Tavares D . IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther. 2015; 14(7):1605-13. DOI: 10.1158/1535-7163.MCT-14-1095. View

11.

Dainty L, Risinger J, Morrison C, Chandramouli G, Bidus M, Zahn C . Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol. 2007; 105(3):563-70. DOI: 10.1016/j.ygyno.2006.10.063. View

12.

Senol S, Ceyran A, Aydin A, Zemheri E, Ozkanli S, Kosemetin D . Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia. Int J Clin Exp Pathol. 2015; 8(5):5633-41. PMC: 4503146. View

13.

Guertin A, ONeil J, Stoeck A, Reddy J, Cristescu R, Haines B . High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. Mol Cancer Ther. 2016; 15(8):1998-2008. DOI: 10.1158/1535-7163.MCT-15-0950. View

14.

Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F . Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol. 2013; 130(1):192-9. DOI: 10.1016/j.ygyno.2013.03.024. View

15.

Elnakat H, Ratnam M . Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004; 56(8):1067-84. DOI: 10.1016/j.addr.2004.01.001. View

16.

Zhang Z, Wang J, Tacha D, Li P, Bremer R, Chen H . Folate receptor α associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2013; 138(7):890-5. DOI: 10.5858/arpa.2013-0309-OA. View

17.

Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G . Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2009; 28(6A):3567-72. View

18.

Vergote I, Marth C, Coleman R . Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015; 34(1):41-52. DOI: 10.1007/s10555-014-9539-8. View

19.

Marchetti C, Palaia I, Giorgini M, DE Medici C, Iadarola R, Vertechy L . Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther. 2014; 7:1223-36. PMC: 4096491. DOI: 10.2147/OTT.S40947. View

20.

Sato S, Itamochi H . Profile of farletuzumab and its potential in the treatment of solid tumors. Onco Targets Ther. 2016; 9:1181-8. PMC: 4789847. DOI: 10.2147/OTT.S98242. View